Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss a distribution agreement with Medusa 19 for its rapid antigen test direct to consumer. Alastair talks us through this latest news, provides an update on the development of the tests and provides details around the potential Affimer treatment for COVID 19.

Avacta Group’s Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Find more news, interviews, share price & company profile here for:
Avacta Group Plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Potential Treatment for COVID-19
Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions